WALTHAM, Mass.--( BUSINESS WIRE )-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 20, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Blaine McKee , Ph.D. has been appointed Executive Vice President and Chief Business Officer.
FORWARD I trial has completed full enrolloment; top-line results expected in the first half of 2019 WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 26, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that
WALTHAM, Mass. --(BUSINESS WIRE)--May 2, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Deutsche Bank 43 rd Annual Health Care Conference .
Patient Enrollment in FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine Completed Ahead of Schedule; On Track for Top-Line Results in the First Half of 2019 Encouraging Data Reported from FORWARD II Assessment of Mirvetuximab with Keytruda ® ; Additional Combination Data to be Presented in 2018,
Data from Avastin Cohort to be Presented at 2018 ASCO Annual Meeting Updated Data from Carboplatin Dose-Escalation Cohort Demonstrate Increased Response Rate and Durable Benefit with Longer-Term Follow Up Conference Call Scheduled for 8 a.m. ET on Thursday, May 17 WALTHAM, Mass.
WALTHAM, Mass. --(BUSINESS WIRE)--May 30, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference.
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 5, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price